<a href="https://laohu8.com/S/OCGN">Ocugen</a> Inc. and Kwangdong Pharmaceutical Finalize $7.5 Million License Agreement for OCU400 Gene Therapy in Korea
Ocugen, Inc., a leader in gene therapies for blindness diseases, has announced a licensing agreement with Kwangdong Pharmaceutical Co., Ltd. for the exclusive rights to OCU400, a novel modifier gene therapy for retinitis pigmentosa, in Korea. The agreement includes upfront fees and near-term development milestone payments totaling up to $7.5 million, with potential sales milestones of $180 million or more in the first ten years of commercialization. Ocugen will also receive a 25% royalty on net sales, while manufacturing and supplying OCU400 under a supply agreement. With an estimated 7,000 individuals affected by retinitis pigmentosa in Korea, this partnership is set to make a significant impact in the field of ophthalmic gene therapy. Ocugen is advancing OCU400 through Phase 3 clinical development, with a U.S. Biologics License Application filing targeted for 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9528654-en) on September 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.